Premalignant epithelial disorders of the vulva: squamous vulvar intraepithelial neoplasia, vulvar Paget's disease and melanoma in situ

Authors

  • ANNELINDE TERLOU,

    Corresponding author
    1. Departments of Obstetrics and Gynecology, Erasmus University Medical Center, Rotterdam, The Netherlands
      Annelinde Terlou, Department of Obstetrics and Gynecology, Erasmus University Medical Center, room Hs-508, P.O. Box 2040, 3000 CA Rotterdam, The Netherlands. E-mail: a.terlou@erasmusmc.nl
    Search for more papers by this author
  • LEEN J. BLOK,

    1. Departments of Obstetrics and Gynecology, Erasmus University Medical Center, Rotterdam, The Netherlands
    Search for more papers by this author
  • THEO J.M. HELMERHORST,

    1. Departments of Obstetrics and Gynecology, Erasmus University Medical Center, Rotterdam, The Netherlands
    Search for more papers by this author
  • MARC VAN BEURDEN

    1. Department of Gynecology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
    Search for more papers by this author

Annelinde Terlou, Department of Obstetrics and Gynecology, Erasmus University Medical Center, room Hs-508, P.O. Box 2040, 3000 CA Rotterdam, The Netherlands. E-mail: a.terlou@erasmusmc.nl

Abstract

No standard screening programs exist to detect vulvar carcinoma or its precursor lesions, and therefore gynecologists, dermatologists and other healthcare providers in this field should be aware of the clinical features, behavior and management of the different existing premalignant vulvar lesions, squamous vulvar intraepithelial neoplasia (VIN), vulvar Paget's disease and melanoma in situ. In 2004, a new classification for squamous VIN was introduced by the International Society for the Study of Vulvar Disease, subdividing squamous VIN into the HPV-related usual type, and into differentiated type, which is associated with lichen sclerosus. This review describes the relevant aspects of squamous VIN, vulvar Paget's disease and melanoma in situ, its epidemiological characteristics, diagnosis, management and malignant potential.

Ancillary